Top-News
Montag,
11.06.2012 21:00
von
PR Newswire
| Aufrufe: 202
XTL Biopharmaceuticals Joins Two Additional Indexes on TASE
Labormitarbeiter bei der Arbeit. (Symbolbild).
© sanjeri / E+ / Getty Images
http://www.gettyimages.de
PR Newswire
HERZLIYA, Israel, June 11, 2012
HERZLIYA, Israel, June 11, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE:XTL,OTC:XTLBY), a biopharmaceutical development company, announces it has been notified by the Tel Aviv Stock Exchange (TASE) that XTL's shares will be included in the following TASE Indexes; "TA MidCap-50" and "TA BlueTech-50", in addition to the "TA-Biomed" and "TA Composite" (also known as the "Yeter" index) indexes which already includes XTL shares since December 2010.
TASE will conduct "special trading" in XTL's shares at the end of trading on June 14, 2012 and the inclusion in the indexes will become effective on June 17.
"We are happy to have been selected to be included in the two indexes", said David Grossman, CEO of XTL, "This is another positive indication for the Company's progress".
TASE'sTA BlueTech-50 Index is a stock market index of the 50 most highly capitalized Information technology and Biotechnology companies listed on TASE.
TASE'sTA MidCap-50 Index is a stock market index of the largest 50 companies not included in TA-100 Index.
About XTL Biopharmaceuticals Ltd. ("XTL)
XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.
XTL's lead drug candidate, rHuEPO for the treatment of multiple myeloma blood cancer was granted an orphan drug designation from the FDA. rHuEPO, has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world for the treatment of severe anemia.
XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).
For more information, please contact XTL Investor Relations at Tel: +972-9-955-7080 or email: ir@xtlbio.com, lucy.kalus@newlook.com
SOURCE XTL Biopharmaceuticals Ltd
Werbung
Mehr Nachrichten zur Anoto Group Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
